23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure.

          Related collections

          Author and article information

          Journal
          JAMA
          JAMA
          American Medical Association (AMA)
          1538-3598
          0098-7484
          Mar 28 2007
          : 297
          : 12
          Affiliations
          [1 ] Division of Cardiology, Tufts-New England Medical Center, Boston, Mass, USA. mkonstam@tufts-nemc.org
          Article
          297.12.1319
          10.1001/jama.297.12.1319
          17384437
          4bbaf292-7485-49d4-9993-7bdcf69b9c87
          History

          Comments

          Comment on this article